The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and human PDE6 gamma, catalog ab5664. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (70-fold) for competitive inhibition of antibody-protein binding reactions.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
5''-cyclic phosphodiesterase subunit gamma
Phosphodiesterase 6G cGMP Specific
Phosphodiesterase 6G cGMP specific rog gamma
Retinal Rod Photoreceptor cGMP Phosphodiesterase gamma
Retinal rod rhodopsin sensitive cGMP 3' 5'vcyclic phosphodiesterase subunit gamma
Retinal rod rhodopsin-sensitive cGMP 3''
Rod cG PDE G
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Involvement in disease
Defects in PDE6G are the cause of retinitis pigmentosa type 57 (RP57) [MIM:613582]. RP57 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.
Belongs to the rod/cone cGMP-PDE gamma subunit family.